Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · IL0011319527 TA Manufacturing
Open in API
Filings indexed 485 across all filing types
Latest filing 2020-11-12 Regulatory Filings
Country IL Israel
Listing TA ENLV

About Enlivex Therapeutics Ltd.

https://enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. It is focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to treat immune system dysregulation. The therapy works by reprogramming macrophages to resolve hyper-inflammation. Enlivex is evaluating Allocetra™ in clinical trials for the treatment of multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis. The product candidate offers flexible administration options, including systemic intravenous infusion and targeted local injections.

Recent filings

Filing Released Lang Actions
Enlivex to Present Schedule for Sepsis, COVID-19 and Solid Cancer Programs at H.C. Wainwright’s 6th Annual Israel Conference
Regulatory Filings Classification · 1% confidence The document is explicitly identified as a 'Form 6-K' filed with the SEC. A Form 6-K is used by Foreign Private Issuers to report material information that is not required to be reported on a schedule or report under the Exchange Act. The content is a press release announcing that the company will present clinical development schedules at an upcoming conference (H.C. Wainwright's 6th Annual Israel Conference). This type of announcement, which is a material event disclosed via a press release and filed on Form 6-K, does not fit neatly into the specific categories like 10-K (Annual Report), ER (Earnings Release), or IP (Investor Presentation). Since it is a general regulatory filing containing material, non-periodic information that doesn't match a more specific category, the most appropriate fallback classification is Regulatory Filings (RNS).
2020-11-12 English
Enlivex to Present Schedule for Sepsis, COVID-19 and Solid Cancer Programs at H.C. Wainwright’s 6th Annual Israel Conference
Report Publication Announcement Classification · 1% confidence The document is a very short filing (1754 characters) submitted to the Israel Securities Authority and the Tel Aviv Stock Exchange. It explicitly states 'Immediate Report' under Regulation 4 and, crucially, contains the line: 'Attached hereto is a report on *6-k* *6k12112020_isa.pdf*'. This structure indicates that the document itself is an announcement about an attached or linked report (a Form 6-K, which is a general SEC filing for foreign private issuers, often used for material events). According to Rule 2, when a document is short and announces the publication of another report, it should be classified as a Report Publication Announcement (RPA). Since '6-K' is a general report type not specifically listed, and this document is merely announcing its attachment, RPA is the most appropriate classification based on the provided definitions and rules.
2020-11-12 English
Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn’s Disease, and Ulcerative Colitis with Allocetra Immunotherapy
Regulatory Filings Classification · 1% confidence The document explicitly states it is a "Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934" and is filed on "Form 6-K" for the month of November 2020. Form 6-K filings are typically used by foreign private issuers to report material information to the SEC, often including press releases. The content is a press release announcing a patent allowance for their product candidate, Allocetra™. This type of material, non-periodic disclosure by a foreign private issuer, is generally categorized under the general regulatory filing umbrella. Since there is no specific code for Form 6-K, and it is a regulatory filing containing material news, the most appropriate general category is Regulatory Filings (RNS), as it is not an Earnings Release (ER), Interim Report (IR), or Annual Report (10-K).
2020-11-05 English
Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn’s Disease, and Ulcerative Colitis with Allocetra Immunotherapy
Report Publication Announcement Classification · 1% confidence The document is very short (1754 characters) and explicitly states, "Attached hereto is a report on *6-k* *6K05112020_isa.pdf*". This structure indicates that the document itself is an announcement about the publication of another report (a Form 6-K, which is a general report filed by foreign private issuers with the SEC). According to Rule 2, when a document is short and announces the availability of a report, it should be classified as a Report Publication Announcement (RPA). Since this is a regulatory filing announcement, RPA is the most appropriate specific category, although RNS could also apply as a fallback. Given the explicit mention of publishing a report, RPA is preferred over the general RNS.
2020-11-05 English
Israeli Ministry of Health Authorizes Initiation of Phase IIb Clinical Trial Evaluating Safety and Efficacy of Allocetra in Sepsis Patients
Regulatory Filings Classification · 1% confidence The document is explicitly titled 'Form 6-K' and is filed with the 'UNITED STATES SECURITIES AND EXCHANGE COMMISSION'. Form 6-K is the standard filing for a 'Report of Foreign Private Issuer' under the Securities Exchange Act of 1934. The content primarily consists of a press release announcing the authorization of a Phase IIb clinical trial and summarizing prior Phase Ib results for their drug AllocetraTM. While it contains detailed clinical information, the primary regulatory wrapper is the 6-K filing itself, which is a periodic/current report for foreign private issuers. Since there is no specific category for Form 6-K, and this document is a current report containing significant operational/clinical updates, it best fits the general 'Regulatory Filings' category (RNS) as a catch-all for non-standard SEC forms, or potentially 'LTR' if the focus was purely on regulatory/legal action, but RNS is more appropriate for general current reports not covered by other specific types like 10-K or ER. Given the options, RNS (Regulatory Filings) is the most suitable fallback for a Form 6-K that isn't an earnings release or annual report.
2020-11-03 English
Israeli Ministry of Health Authorizes Initiation of Phase IIb Clinical Trial Evaluating Safety and Efficacy of Allocetra in Sepsis Patients
Report Publication Announcement Classification · 1% confidence The document is extremely short (1756 characters) and explicitly states, "Attached hereto is a report on *6-K* *03112020_6k_isa.pdf*". This structure—a brief announcement pointing to an attached or linked external document—fits the definition of a Report Publication Announcement (RPA) according to the 'MENU VS MEAL' rule. While the attachment is a 6-K (which often contains material information like an Earnings Release or other specific events), this specific filing is merely announcing the publication of that 6-K report, not containing the full content of the report itself. Therefore, RPA is the most appropriate classification for this announcement wrapper.
2020-11-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.